the DBLreport

Issue #105, November 2018

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

In this issue:

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on September 20, 2018. The Committee reviewed Manufacturer submissions for twenty-one (21) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a number of supplementary assessments of the coverage status of four (4) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, six (6) Drug Products underwent Expedited Review for listing on the *ADBL* effective October 1, 2018, and sixteen (16) Drug Products underwent Expedited Review for listing on the *ADBL* effective November 1, 2018.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at https://www.ab.bluecross.ca/dbl/publications.html

Highlights of Drug Products Added

The following Drug Product was reviewed by the Expert Committee and added to the *Alberta Drug Benefit List (ADBL)* effective October 1, 2018:

- **PLAN B** (levonorgestrel) (TEP) **1.5 mg tablet**

Highlights of Interchangeable (IC) Drug Products Added

Addition of the following Entry IC Drug Products to the *ADBL* has resulted in the creation of a New IC Grouping, effective November 1, 2018:

- **APO-LANSOPRAZOLE-AMOXICILLIN-CLARITHROMYCIN KIT** (lansoprazole/amoxicillin trihydrate/clarithromycin) (APX)
  30 mg/500 mg/500 mg tablet/capsules
- **JAMP-FOSFOMYCIN** (fosfomycin tromethamine) (JPC) **3 g oral powder packet**

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

Changes in Listing Status & Criteria

As part of the Review of Benefit Status (ROBS) process, comprehensive clinical reviews of overactive bladder agents were undertaken by the Expert Committee. Following discussion and examination of all information available, the Committee recommended listing changes to these agents on the *ADBL*. As of October 1, 2018, the listing status of the following Drug Products has been changed from Step Therapy/Special Authorization to Regular Benefits:

- **SOLIFENACIN** (solifenacin succinate) **5 mg & 10 mg tablets** (all brands)
- **TOLTERODINE** (tolterodine l-tartrate) **2 mg & 4 mg long-acting capsules** (all brands)

Accordingly, effective October 1, 2018, the Step Therapy/Special Authorization criteria for coverage for the following Drug Products have been revised:

- **ENABLEX*** (darifenacin hydrobromide) (MLL) **7.5 mg & 15 mg extended-release tablets**
- **TOVIAZ*** (fesoterodine fumarate) (PFI) **4 mg & 8 mg extended-release tablets**
- **MYRBETRIQ*** (mirabegron) (ASP) **25 mg & 50 mg extended-release tablets**
- **TROSEC*** (trospium chloride) (SUN) **20 mg tablet**

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*
ABC 81171 (11/2018)